



Corporate Brochure

SPECIAL 100-YEAR EDITION

RECORDATI

Via Matteo Civitali, 1
20148 Milan, Italy
Ph. +39 02 48 787.1
www.recordati.com

1926
2026
100 RECORDATI



1926
2026

1926

2026

Our first 100 years

In the 19th century, the Recordati family ran a small pharmacy in Correggio, Northern Italy, serving their local community. In 1926, at the age of 28, Giovanni Recordati moved from experimenting in the back of that same pharmacy to founding a company: the "Laboratorio Farmacologico Reggiano."

One hundred years later, in 2026, we stand as a global pharmaceutical group with a presence in over 150 countries, committed to unlocking the full potential of life. Our centenary is not just a celebration of longevity, it is a confirmation of our purpose, values, continuity, and care.

At Recordati, we have always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether addressing common conditions or the rarest diseases, we are committed to giving everyone the opportunity to be the best version of themselves. This commitment will not waver.

Recordati has a long history of entrepreneurial passion, a strong reputation, and a clear ambition to continue growing, innovating, and creating value in an ethical, enduring, and sustainable way—protecting people and the environment, and providing safe, high-quality products.

1926

2026

1926
2026
100

1926



Our centenary is not just a celebration of longevity – it is a confirmation of our purpose, values, continuity and care. As we mark this milestone, we honour the legacy of the people, patients and partners who shaped our journey, and embrace the responsibility of shaping the next 100 years.



1926
2026



100 years behind us.
Infinite possibilities ahead.

1926 2026

*Milestones of a
100-year success story*

1 MAY:
FOUNDATION
DATE

1926



- 1984 • Listing on the Italian **Stock Exchange**
- 1986 • Launch of **Lomexin**®, dermatological and gynaecological antimycotic discovered and developed within Recordati (P)




BEGINNING OF
INTERNATIONAL
EXPANSION

1995



ENTRY INTO THE US
MARKET FOR RARE DISEASES

2013



ENTRY INTO ENDOCRINOLOGY
AND EXPANSION OF PORTFOLIO

2019



2022/2026

ENTRY INTO RARE ONCOLOGY
AND EXPANSION OF PORTFOLIO

- 1926 • Founding of **Laboratorio Farmacologico Reggiano** in Correggio, **Italy**
- 1927 • Launch of **Antispasmina Colica**®, gastrointestinal antispasmodic (P)
- 1935 • Launch of **Tefamin**®, cardiotonic, diuretic and antihypertensive (P)
- 1938 • Launch of **Simpamina**®, stimulant of the autonomic nervous system (P)
- 1953 • Relocation of headquarters to Milan, **Italy** (G)
- 1956 • Launch of **Recordil**®, for inflammatory and pain-related conditions (P)
- 1957 • Acquisition of Pravaz in **Brazil** (C)
- 1961 • Establishment of subsidiary in **Mexico** (G)
- 1962 • Launch of **Remeflin**®, for the treatment of gastrointestinal disorders (P)
- 1963 • Inauguration of the first pharmaceutical chemical plant in **Campoverde** di Aprilia, **Italy** (G)
- 1973 • Launch of **Genurin**®/**Urispas**®, urinary antispasmodic discovered and developed within Recordati, first Italian drug approved by the FDA (P)

1984

12 OCTOBER: LISTING
ON THE ITALIAN
STOCK EXCHANGE

- 1995 • Establishment of subsidiary in **Spain** (G)
- 1997 • Launch of **Zanidip**®, new antihypertensive, discovered and developed within Recordati (P)
- 1999 • Acquisition of Doms Adrian in **France** (C)
- 2000 • Acquisition of Laboratoires Bouchara in **France** (C) and its portfolio including **Polydexa**®, for ENT (Ear, Nose and Throat) infections; **Methadone**®, for opioid dependency treatment (P)
- 2004 • Licence agreement for **Urorec**®, for benign prostatic hyperplasia (BPH) (P)
- 2005 • Acquisition of Merckle Recordati in **Germany** (C)
- Establishment of subsidiary in **UK** (G)
- Establishment of subsidiary in **Greece** (G)
- Opening of the pharmaceutical chemical plant in Cork, **Ireland** (G)
- 2006 • Acquisition of Grupo Jaba in **Portugal** (C)

2007

ENTRY INTO THE RARE
DISEASES SECTOR



- 2007 • Acquisition of Orphan Europe in **France** (C) and its global portfolio including **Carbaglu**®, **Cystadane**®, **Cystadrops**®, **Pedea**®, treatments for rare metabolic disorders (P)
- Launch of **Zanipress**®, antihypertensive (P)
- 2008 • Licence agreement for **Livazo**®/ **Alipza**®, for cardiovascular conditions (P)
- Acquisition of FIC and FIC Médical for **Russia** and **CIS markets** (C)
- Acquisition of Yeni İlaç in **Türkiye** (C)
- 2009 • Acquisition of Herbacos-Bofarma in the **Czech Republic** and **Slovakia** (C)
- 2010 • Licence agreement for **Cardicor**®, for cardiovascular conditions (P)
- Acquisition of ArtMed International in **Romania** (C)
- 2011 • Acquisition of **Procto-Glyvenol**®, haemorrhoid treatment (P)
- Acquisition of Dr. F. Frik İlaç in **Türkiye** (C)
- 2012 • Acquisition of Farma-Projekt in **Poland** (C)
- Acquisition of an expanded CHC portfolio in **Germany** (P)
- Acquisition of a CHC portfolio for **Russia** and **CIS** (P)
- 2013 • Establishment of a fully fledged subsidiary in the **US** (G)
- Acquisition of US rare disease portfolio including **Panhematin**®, **NeoProfen**®, and **Cosmegen**®, expanding into rare, neonatology, and inflammatory diseases (P)
- Acquisition of Opalia Pharma and production facilities in **Tunisia** (C)
- Acquisition of Laboratorios Casen Fleet (C) and production facilities in **Spain**, including **Citrafleet**®, bowel preparation for gastrointestinal procedures (P)
- Establishment of subsidiary in **Ukraine** (G)
- 2014/
2015 • Establishment of subsidiaries in **Brazil**, **Mexico** and **Colombia** (G)

2016

STRENGTHENING OF
SPECIALTY & PRIMARY
CARE PORTFOLIO

- 2016 • Acquisition of Italcimici in **Italy** (C) including its product **Reuflor**®/ **Biogaia**®, for gastrointestinal disorders (P)
- Acquisition of Pro Farma AG in **Switzerland** and **Austria** (C)
- Licence agreement for **Reagila**®, for schizophrenia (P)
- 2017 • Establishment of subsidiary in **Canada** (G)
- Acquisition of **Seloken**® / **Seloken**® ZOK for hypertension and other cardiovascular conditions (P)
- 2018 • Acquisition of full rights to **Cystagon**®, already distributed by Recordati since 2007, for nephropathic cystinosis, (P)
- Acquisition of Natural Point in **Italy** (C), including its product **Magnesio Supremo**®, magnesium dietary supplement (P)
- Licence agreement for **Ledaga**®, for mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) (P)
- Establishment of subsidiaries in **Japan** and **Australia** (G)

- 2019 • Acquisition of endocrinology portfolio including **Signifor**® / **Signifor**® LAR, and **Isturisa**® (P)
- Licence agreement for **Juxtapid**® in Japan, for severe genetic lipid disorders (P)
- Establishment of subsidiary in **Bulgaria** (G)
- 2021 • Licence agreement for **Eligard**®, for prostate cancer (P)
- Licence agreement for **Salaza**®, for ulcerative colitis (P)

- 2022 • Acquisition of EUSA Pharma in **UK** (C) and its global rare oncology portfolio including **Sylvant**®, **Qarziba**®, **Fotivda**®, **Caphosol**® (P)
- 2023 • Commercialisation agreement for **Avodart**® and **Combodart**®/ **Duodart**®, for benign prostatic hyperplasia (BPH) (P)
- 2024 • Reinforcement of Recordati Rare Diseases MENA presence with opening of subsidiary in **Saudi Arabia** (G)
- Establishment of subsidiary in **Argentina** (G)
- Acquisition of global rights to **Enjaymo**®, for cold agglutinin disease (CAD) (P)
- 2025 • FDA approval of an expanded indication for **Isturisa**® for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome (P)
- Licence agreement for **Vazkepa**®, for statin-treated patients with high cardiovascular risk (P)
- Licence agreement for **Inrebic**® in Japan, for types of myelofibrosis (P)
- 2026 • Licence agreement for **mRNA-3927**, for propionic acidemia (P)


LEGEND:
(C) Company acquisition
(P) Product acquisition or licence
(G) Geographic expansion

Disclaimer:
The acquisitions, agreements and regulatory milestones shown in this timeline may refer to specific countries, markets or therapeutic indications and may not apply globally.



Table of contents

| | | |
|------------|---|----|
| 01. | Continuing our growth journey | |
| | Our purpose and values | 9 |
| | Recordati at a glance | 10 |
| | Growing through innovation and new treatments for global patient care | 12 |
| | Recordati's key figures | 13 |
| 02. | Headquarters in Milan activities worldwide | |
| | Business overview: Specialty & Primary Care | 15 |
| | Business overview: Rare Diseases | 20 |
| | Business overview: Industrial Operations | 25 |
| | Research & Development at Recordati | 27 |
| 03. | The key to collaborative success | |
| | Business Development: Partnering & Strategy | 29 |
| | Selected Partnerships | 30 |
| 04. | Working for patients, with patients | |
| | Patient Partnership | 33 |
| 05. | Sustainable and responsible growth | |
| | Recordati's commitment to sustainability | 35 |





01 continuing our growth journey —

Our purpose and values

Driven by our purpose, we are focused on improving people's health and quality of life. We care for our people and strive to provide them with the opportunities and support to grow.

We pursue a long-term, sustainable growth model, integrating social and environmental considerations into our strategy to contribute positively to the communities in which we operate—while consistently generating value for our stakeholders.

Our values:

Better together

We believe that when we work together, we are stronger and create magic.

Never settle

We believe that reaching our potential comes through courage, innovation and hard work.

Always deliver

We believe that trust is built from doing what you say you will, when you say you will.

Our non-negotiables:


Underpinning our values are two non-negotiables that apply to everyone, at all times—without compromise:

Patients are fundamental

They must be at the heart of everything we do.

Integrity is fundamental

It goes beyond honesty—it means doing the right thing at all times, even when it is difficult or when no one is watching.





Figures and data from the Recordati Annual Report 2025.

Recordati at a glance

We continue to strengthen our position as a global pharmaceutical group, combining scale, focus, and a long-term growth mindset.

We are continually growing, with a focus on developing new specialties, new treatments and investing in medical innovations that bring a brighter future to patients across the world.

Key facts


- Founded in 1926 in Correggio, Northern Italy
- Headquartered in Milan, Italy
- Listed on the Italian Stock Exchange since 1984
- Fully integrated operations across research, development, chemical and finished product manufacturing, through to commercialisation and licensing




PHARMACEUTICAL REVENUE BY THERAPEUTIC AREA

SPECIALTY & PRIMARY CARE **58.7%**

RARE DISEASES **41.3%**



PHARMACEUTICAL REVENUE BY GEOGRAPHY



GROUP HIGHLIGHTS

Net Revenue

2,618.4 million euros

Adjusted Net income

651.1 million euros

EBITDA

991.1 million euros



Employees

~4.7K total employees



Markets

~150 total markets
in EMEA, Americas and APAC Regions



Growing through innovation and new treatments for global patient care

We provide treatments across Specialty & Primary Care, Consumer Healthcare (CHC), and Rare Diseases, with fully integrated research, development, manufacturing, and commercialisation.

Recordati has a strong heritage in treating common illnesses, providing **prescription and self-medication therapies in cardiovascular, urological/uro-oncological, and gastrointestinal areas**—operating globally, with direct presence in Europe, Türkiye, North Africa and MENA region supporting patient access throughout a medicine's lifecycle.

Since 2007, **Recordati Rare Diseases** has focused on providing treatments for the small percentage of patients with Rare Diseases, aiming to reduce their impact in endocrinology, hema-oncology, and metabolic disorders—operating globally, with a presence in the US since 2013.



More than
100 million people

benefitted from our Specialty & Primary Care portfolio




And almost
20,000 patients

living with rare diseases received dedicated treatments

Recordati's key figures


REVENUE

million euros




EBITDA*

million euros




EBITDA*

AS % OF REVENUE




RESEARCH & DEVELOPMENT

million euros




NET INCOME

million euros




ADJUSTED NET INCOME**

million euros




DIVIDEND PER SHARE

euro




NET INCOME PER SHARE

euro



ADJUSTED NET INCOME PER SHARE

euro



* Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3.

** Net income excluding the amortization and write-down of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.



02 headquarters in Milan — activities worldwide

Business overview: Specialty & Primary Care

A strong and proven heritage in supporting people living with a wide range of common conditions that affect large populations every day.

We take pride in unlocking the value of some of the world's most trusted pharmaceutical brands, relied on by millions of patients worldwide. We create value for patients, payers, and physicians through our portfolio, bringing affordable innovation to both prescription and self-medication markets.

Prescription medicines

We have a strong presence in this field, offering established treatments across cardiovascular, urological and uro-oncological, and gastrointestinal diseases. Our portfolio includes products developed through our own research as well as through targeted licensing agreements.

Consumer Healthcare

We offer a portfolio of well recognised brands across a broad range of categories, including digestive health, women's health and intimate care, as well as vitamins, minerals, and food supplements.

 **RECORDATI**
Focused on You

FOCUS AREAS


- Cardiovascular
- Urology and uro-oncology
- Gastroenterology
- Cough and Cold

~400 brands

HIGHLIGHTS

▲ Subsidiaries, branches, permanent establishment and direct promotion

▲ Licensees, distributors, commercial agreements



Years 2024-2025



Cardiovascular

Cardiovascular diseases affect the heart and blood vessels and are often associated with arterial damage, which can impair the function of vital organs. For almost 30 years, we have supported patients living with cardiovascular conditions, across both primary and secondary care. We have built a broad and well-established cardiovascular portfolio over more than two decades, including treatments discovered, developed, and marketed by Recordati. Key products include:

ZANIDIP®/CORIFEQ®/LERCADIP® (*lercanidipine*)
Antihypertensive

ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®
(*lercanidipine + enalapril*)
Antihypertensive

SELOKEN®/SELOKEN®ZOK/BETALOK®ZOK
(*metoprolol succinate*)
Angina pectoris, disturbances of cardiac rhythm,
hypertension

LIVAZO®/ALIPZA® (*pitavastatin*)
Hypercholesterolaemia

VAZKEPA® (*icosapent ethyl*)
Statin-treated patients with high cardiovascular risk

Urology and uro-oncology

Urological diseases affect the urinary and reproductive systems and may originate within these systems or result from disorders in related organs such as the kidneys, ureters, bladder, and prostate. We are a recognised partner in urology, providing therapeutic solutions that support both men's and women's health. Our portfolio addresses a wide range of conditions, including prostate cancer, benign prostatic hyperplasia (BPH), overactive bladder (OAB), and infection-related diseases. Key products include:

ELIGARD® (*leuprorelin acetate*)
Hormone dependent advanced prostate cancer

AVODART® (*dutasteride*)*
Benign Prostatic Hyperplasia (BPH)

COMBODART®/DUODART® (*dutasteride/tamsulosin*)*
Benign Prostatic Hyperplasia (BPH)

UROREC®/SILODYX® (*silodosin*)
Benign Prostatic Hyperplasia (BPH)

These treatments support millions of men worldwide, addressing moderate to severe BPH symptoms and reducing the risk of complications.

Gastroenterology

Gastroenterological conditions affect the gastrointestinal tract, the core system responsible for digestion. We offer a diversified portfolio of prescription and self-medication solutions, supporting the diagnosis and treatment of both upper and lower gastrointestinal conditions. Our portfolio includes well-established brands such as:

CITRAFLEET® (*citric acid*), **PHOSPHOSODA®**
(*sodium dihydrogen phosphate dihydrate*)
Bowel evacuants

CASENLAX® (*macrogol*), **FLEET ENEMA®**
(*monobasic sodium phosphate*)
Constipation and bowel cleansing

* Trademarks are owned by or licensed to the GSK group of companies. Transition to Recordati of commercialisation of Avodart® and Combodart®/Duodart® has been enacted in the following markets: Austria, Belgium, Czech Republic, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Poland, Portugal, Spain, Sweden, Switzerland, UK.



Cough and Cold

The Respiratory System and our overall health is impacted by seasonal conditions such as Cough and Cold. We support everyday wellbeing and relieving common symptoms that can impact respiratory function through both prescription and self-care treatments, with a particular focus on cough and cold, while also addressing selected wider respiratory conditions such as asthma. Our Portfolio Includes:

POLYDEXA® (*neomycin sulfate*)
Treatment of ear infections

ISOFRA® (*framycetin sulfate*)
Treatment of nose and throat infections

AIRCORT® (*budesonide*)
Treatment of bronchial asthma and respiratory inflammation

These products are successfully marketed across Italy, France, Russia, and CIS (Commonwealth of Independent States) countries.

Other

TERGYNAN® (*metronidazole*)
Gynecological infections

REAGILA® (*cariprazine*)
Antipsychotic

Main Consumer Healthcare brands

MAGNESIO SUPREMO® (*magnesium carbonate*)
Food supplement

PROCTO-GLYVENOL® (*tribenoside + lidocaine*),
PROCTOLYN® (*fluocinolone acetonide + ketocaine hydrochloride*)
Treatment of haemorrhoids


LOMEXIN®/FALVIN®/GYNOXIN®
(*fenticonazole*)
Antifungal

REUFLOR®, REUTERI®, CASENBIOTIC®, BIORALSUERO® (*lactobacillus reuteri protectis*)
Probiotics

HEXASPRAY® (*biclotymol*)
Antibacterial for sore throat

Empowering patients

We continue to advance targeted initiatives to strengthen education, normalise conversations, and encourage confident, responsible self-care.



GO BEYOND

GO BEYOND reflects our ongoing commitment to supporting men diagnosed with prostate cancer, offering clear guidance, practical tools, and reassurance to help them regain confidence and purpose. Over the past year, the programme has continued to evolve, with materials now available in several countries and through international partners. These have been adapted into a range of practical resources, including exercise, nutrition, and lifestyle guidance.

Breaking the Taboo

#IHadItToo reflects our commitment to breaking taboos empowering young women with the knowledge and support they need to understand intimate infections. The programme in Poland offers accessible explanations of common causes, easy-to-follow symptom checklists, and evidence-based treatment pathways to elevate education, normalise conversation, and encourage confident, responsible self-care.

Health Caravan

The Health Caravan project continues in Tunisia, aiming to strengthen access to specialised medical care in underserved rural areas. Through the dedication of a multidisciplinary team of healthcare professionals, including cardiologists and pulmonologists, the initiative delivered over 1,000 specialised consultations—providing tangible support to communities facing persistent barriers to healthcare access.

Business overview: Rare Diseases

Our Rare Diseases business unit is fully dedicated to the research, development, and commercialisation of treatments for rare conditions, operating on a global scale.

There are over 7,000 known rare diseases, yet approved treatments exist for fewer than 10% of them—highlighting the significant unmet medical need in this field. We are driven by the conviction that every person living with a rare disease has the right to the best possible treatment, and we are committed to advancing solutions that can make a meaningful difference in patients' lives.



**RECORDATI
RARE DISEASES**
Focused on the Few


FOCUS AREAS

- Endocrinology
- Hema-Oncology
- Metabolic

~20 brands

HIGHLIGHTS

- ▲ Subsidiaries, branches, permanent establishment and direct promotion
- ▲ Licensees, distributors, commercial agreements



Years 2024-2025.
The activities of the Beijing affiliate ceased on 31 December 2025. Distribution, license and supply agreements for China remain in place.




Endocrinology

The endocrine system is a network of glands that produce and secrete hormones, which act as chemical messengers regulating key bodily functions such as growth, metabolism, reproduction, and overall wellbeing. Endocrine diseases disrupt normal hormone production and, if left untreated, can lead to serious—sometimes life-threatening—conditions. Many of these diseases are rare and affect small patient populations worldwide. We entered key endocrine specialty areas in 2019, focusing on rare conditions such as Cushing's disease/Cushing's syndrome and acromegaly—disorders that can significantly impact quality of life. Our presence in this field has been strengthened through the acquisition of:

SIGNIFOR®/SIGNIFOR® LAR (pasireotide)
Treatment of Cushing's disease and acromegaly

ISTURISA® (osilodrostat)
Treatment of Cushing's disease and Cushing's syndrome

In April 2025, Isturisa® received U.S. approval for label expansion to endogenous hypercortisolaemia in Cushing's syndrome.





Hema-Oncology

The human body is composed of trillions of cells that continuously renew themselves through tightly regulated processes of growth and division. Cancer can develop when these processes are disrupted, leading to the uncontrolled growth of abnormal cells, which may form tumours. These can be malignant—spreading to other parts of the body—or benign, typically remaining localised. We entered the field of rare oncological and haematological diseases with the acquisition of EUSA Pharma in March 2022, establishing a focused portfolio in specialised and high-need indications. Global access to these therapies continues to expand. Our portfolio includes treatments for rare and niche conditions such as:

ENJAYMO® (*sutimlimab*)

A groundbreaking biologic and the only approved targeted treatment for cold agglutinin disease (CAD), a rare and debilitating B-cell lymphoproliferative disorder

QARZIBA®

(*dinutuximab beta, anti-GD2 monoclonal antibody*)
Treatment of high-risk neuroblastoma patients aged 12 months and above, who achieved at least a partial response at the chemotherapeutic induction, followed by myeloablative therapy and stem cell transplantation

SYLVANT® (*siltuximab, anti-IL-6 monoclonal antibody*)

Treatment of Idiopathic Multicentric Castleman's disease (iMCD) in adults

FOTIVDA® (*tivozanib, oral highly selective small molecule tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3*)

Treatment of first-line of advanced renal cell carcinoma

CAPHOSOL® (*supersaturated calcium phosphate rinse*)

Prescription medical device for the treatment of oral mucositis caused by chemotherapy and radiotherapy



In 2025, discussions progressed with the FDA regarding the potential regulatory pathway for the Biologics License Application (BLA) for **Qarziba®**, which is already available in Europe and other markets.

In November 2024, we further strengthened our haematology presence with the acquisition of **Enjaymo®** from Sanofi—the only approved targeted therapy for Cold Agglutinin Disease (CAD), a rare autoimmune, complement-mediated haemolytic disorder. The Enjaymo® business was fully integrated into our operations in 2025.

FOCUS ON EXPANSION

Metabolic and other therapeutic areas

Metabolic diseases can arise from genetic defects that lead to the abnormal accumulation of certain metabolites and/or deficiencies in others. These inborn errors of metabolism can affect patients at any stage of life—from neonates and children to adults—and are often difficult to diagnose. If left untreated, many of these rare conditions can be life-threatening. Since its foundation, our Rare Diseases business has focused on addressing rare metabolic conditions. We entered the field of rare genetic metabolic diseases in 2007, initially building our presence in Europe and the MENA region, before expanding into the United States in 2013. Our legacy metabolic portfolio includes:

CARBAGLU® (*carglumic acid*)

Treatment of hyperammonemia due to N-acetylglutamate synthase deficiency (NAGS deficiency) and some organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia)

NORMOSANG®/PANHEMATIN® (*human hemin*)

Treatment of acute attacks of hepatic porphyria

CYSTADANE® (*betaine anhydrous*)

Treatment of homocystinuria

CYSTADROPS®

(*cysteamine hydrochloride*)

Treatment of the ocular manifestations of cystinosis

JUXTAPID® (*lomitapide*)

Treatment of homozygous familial hypercholesterolemia (HoFH)

CYSTAGON®

(*cysteamine bitartrate*)

Treatment of nephropathic cystinosis

LEDAGA®

(*chlormethine hydrochloride*)

Treatment of mycosis fungoides (MF), T-cell cutaneous lymphoma (CTCL)

PEDEA®/NEOPROFEN®

(*ibuprofene IV*)

Treatment of patent ductus arteriosus (PDA)

VEDROP® (*tocofersolan*)

Treatment or prevention of vitamin E deficiency

WILZIN® (*zinc acetate*)

Treatment of Wilson's disease

MAAPLIV® (*branched-chain amino acid-free amino acids*)

Treatment of acute decompensation episodes of maple syrup urine disease (MSUD)

Supporting the scientific community

We are committed to supporting scientific progress, education, and collaboration—contributing to the advancement of knowledge in areas where unmet medical needs remain significant.



Arrigo Recordati Prize

In 2025, we launched the call for applications for the 2025–2026 edition of the Arrigo Recordati Prize, now in its twelfth edition, dedicated to recognising and supporting researchers who have made a meaningful contribution to paediatric oncology, with a specific focus on sarcomas.



Recordati Rare Diseases Foundation

The Recordati Rare Diseases Foundation continues to support independent, high-level training programmes for the scientific community, guided by an external scientific committee. These initiatives aim to share expertise in the diagnosis and management of rare diseases, where knowledge is often limited.



Unique Partnerships

We supported several scientific societies in sponsoring studies to explore the use of Qarziba® in new stages of the treatment pathway for neuroblastoma and Ewing's sarcoma. We entered into a strategic collaboration with Moderna for the development and global commercialisation of an investigational therapy for propionic acidemia (PA).



Business overview: Industrial Operations

We operate several state-of-the-art production sites, where the manufacturing of finished products and active ingredients is fully integrated with our pharmaceutical activities—supported by advanced research laboratories equipped with the latest technologies.

Our global network also includes over 150 contract manufacturing organisations (CMOs) and 50 warehouses, enabling the delivery of more than 300 million units of medicines and therapies each year.

150+ Contract Manufacturing Organisations (CMO)

40+ logistics providers

130+ countries reached


>300 million units delivered across the globe

Production facilities

7 Pharmaceutical manufacturing plants*

1 Packaging and distribution centre dedicated to products for Rare Diseases

2 Pharmaceutical chemical plants



Tech transfer and lifecycle management

We apply a systematic approach to transferring knowledge, skills, and technologies, managing the full lifecycle of our products—from conception and development through to manufacturing and service. This enables us to build and sustain a strong and ambitious portfolio of technology transfer projects.

Quality and safety

We continuously invest to keep our production lines and facilities at the forefront of technology. Our focus is on strengthening QHSE management and enhancing production capacity, efficiency, and flexibility—ensuring the highest standards of quality and patient safety.

Pharmaceutical Chemicals

We use a broad range of technologies to produce competitively, maintaining the highest quality standards. Our pharmaceutical chemicals business focuses on:

- Satisfying the requirements of the pharmaceuticals business.
- Striving for maximum product quality.
- Strengthening our presence in highly regulated markets (the United States, Europe and Japan).
- Safety of production processes.
- Protection of the environment.
- Health and safety in the workplace.



Research & Development at Recordati

We have always focused on developing and offering innovative products that improve human health and quality of life, while aspiring to be a top-tier value creator for patients, investors, and employees alike.

We continuously invest in research and development and are committed to maintaining the highest standards of quality and safety throughout the entire product lifecycle.

R&D expenses
341 million euros*

* This amount includes amortization of the rights relating to products acquired.



the key to collaborative success

03

Business Development: Partnering & Strategy

Our proven ability to build strong, value-creating partnerships with leading players in the pharmaceutical sector supports our ongoing efforts to identify new opportunities and establish licensing agreements for the development of high-value medicines in areas of unmet medical need.

We actively seek in-licensing and acquisition opportunities, as well as innovative technologies, to strengthen our pipeline and portfolio and foster continued innovation.

We build long-term, value-creating partnerships with high-quality players across the pharmaceutical sector. Our integrated structure—spanning Specialty & Primary Care, Consumer Healthcare, and Rare Diseases—enables us to bring treatment options that benefit the lives of patients and consumers efficiently across the full value chain, from development to commercialisation.

Capabilities & global reach

- Fully integrated operations across development, registration, manufacturing, and commercialisation
- Present in over 150 countries, complemented by partnerships in markets

Focus

- A “local brilliance” commercial approach, tailored to each market to maximise growth opportunities
- Focus on a selected portfolio of strategic products that deliver value to patients, payers, and physicians
- Strong ownership mindset: we treat each partnered product as if it were our own

Track record

- Flexible and creative deal structures to share value with partners
- Long-term strategic partnerships
- Over 35 transactions completed in the past 15 years

SPECIALTY & PRIMARY CARE (SPC)

We target innovation from late clinical stage through to marketed products in:

- Cardio-metabolism
- Urology / uro-oncology
- Gastrointestinal diseases

We also consider promotionally sensitive established brands across a broad range of therapeutic areas.

CONSUMER HEALTHCARE (CHC)

We focus on well recognised, marketed products, particularly in the following categories:

- Digestive health
- Women’s health and intimate care
- Cough and Cold
- Vitamins and Supplements

RARE DISEASES (RD)

We focus on innovative products ranging from clinical proof of concept to marketed products, across all therapeutic areas, with particular attention to:

- Rare endocrinology
- Rare metabolic diseases
- Rare oncology
- Rare haematology



Selected Partnerships

| LICENSOR | TRADEMARK | THERAPEUTIC AREA |
|---|-----------------------------------|------------------|
|  | Juxtapid® | Rare metabolism |
|  | Qarziba® | Rare oncology |
|  | Fotivda® | Rare oncology |
|  | Reagila® | CNS |
|  | Avodart® and Combodart®/ Duodart® | Urology |
|  | Ledaga® | Onco-dermatology |
|  | Urorec®/Silodyx™/ Silosin® | Urology |

* Trademarks are owned by or licensed to the GSK group of companies.

** Investigational therapy.

| | | |
|---|-------------------|------------------|
|  | Livazo®/Alipza® | Cardiometabolism |
|  | Reselip® | Cardiometabolism |
|  | Fortacin™ | Urology |
|  | Rizmoic® | Gastrointestinal |
|  | Vitaros®/Virirec® | Urology |
|  | Peptazol® | Gastrointestinal |
|  | Eligard® | Uro-oncology |
|  | Vazkepa® | Cardiometabolism |
|  | mRNA-3927** | Rare metabolism |



Patient Partnership

In our partnership strategy patients are non-negotiable.

At Recordati, patient partnership represents a powerful opportunity to co-create therapies and innovations that truly address outcomes that matter. Our integrated strategy aims to help us move beyond ad hoc involvement to systematic engagement across the entire drug development lifecycle and patient journey.

By embedding lived experiences into trial design, regulatory dialogue, and strategic decision-making, we strive to ensure that outcomes most important to patients are reflected in every stage of medicines development and beyond.

Our commitment to the patient community

We deeply value the opportunity to collaborate with patients, recognising the richness of their insights, lived experiences, and specialised knowledge.

These partnerships are essential in helping us better understand how to meaningfully integrate the patient viewpoint throughout the development and delivery of our medicines. Only by gathering relevant patient insights, are we able to learn more about the patient lived experience, which ultimately helps us to develop and commercialise products that match patients' needs.



04 working
for patients,
—— with
patients






05 sustainable and responsible growth —

Recordati's commitment to sustainability

We have a long history of entrepreneurial passion, a strong reputation, and a clear ambition to continue growing and creating value in an ethical, enduring, and sustainable way.

We pursue these goals in full compliance with the laws and regulations of the countries in which we operate, while protecting people and the environment and ensuring the delivery of safe, high-quality products.

In our Sustainability Plan we outline our future trajectory that reflects our ambitions and priorities for responsible, long-term growth. It focuses on five key areas: patient care, people care, environmental protection, responsible sourcing, and ethics and integrity. Our efforts to sustainability are recognised by the main ESG indices and ratings.

| | |
|---|--|
|  | Confirmed in the FTSE4Good Index Series |
|  | Confirmed A rating from MSCI ESG Research* |
|  | Recordati group was rated with "prime" status, awarded to companies with a leading sustainability performance in their sector |
|  | EcoVadis awarded the Recordati group with a "Gold" medal |
|  | Inclusion in MIB ESG index launched by Euronext and Borsa Italiana |

2025 MAIN ESG INDICES AND RATINGS

* The use by the Recordati group of any MSCI ESG Research LLC or its affiliates ("MSCI") data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of Recordati Group by MSCI. MSCI services and data are the property of MSCI or its information providers, and are provided 'as-is' and without warranty. MSCI names and logos are trademarks or service marks of MSCI.



Growing responsibly

We pursue a long-term sustainable growth model, integrating social and environmental aspects into the corporate strategy.

This promotes a positive contribution to sustainable development in the areas in which we operate. All this, while also maintaining a commitment to generating value for stakeholders.

Fight against climate change

In 2025, we continued to invest in environmental sustainability, completing the installation of solar panels in Tunisia and Italy (Campoverde – first phase) and expanding the system in Spain, reaching a total installed capacity of approximately 6,200 kWp, including systems already in operation.

Supporting our patients

Approximately 1,450 patients living with rare diseases were supported through our Patient Assistance Programmes, Co-Pay Assistance Programmes, and similar initiatives.

Engaging our people

In addition to donations, many initiatives were run supporting local communities where we operate, through the direct participation of our people in social initiatives.



€ 3.2 million


in donations to the community (including monetary and product donations measured at market value)



1926




Did you know that Recordati's roots go back over 200 years?



The roots of the Recordati story go back to the early 19th century, when Giovanni Battista Recordati acquired a small apothecary in Correggio, Northern Italy. For generations, the family pharmacy served the local community. This passion to help people remained closely tied to the family's history, powering scientific curiosity for years to come.

Did you know that Giovanni Recordati was just 28 years old when he founded the company?



In the early 1920s, Giovanni Recordati began conducting experiments in a small laboratory behind the family pharmacy in Correggio. That work led to the foundation of the Laboratorio Farmacologico Reggiano on 1 May 1926, marking the beginning of what would later become the Recordati Group, now present in around 150 countries worldwide.



Form titled 'CAMERA DI COMMERCIO E INDUSTRIA DI REGGIO EMILIA' and 'DITTA INDIVIDUALE'. It contains registration details for 'Ditta Dr. Giovanni Recordati & C. s.p.a.' in Correggio, including dates and professional classification.

Form titled 'ESERCIZIO NELLA CIRCOSCRIZIONE' and 'DITTE RAPPRESENTATE'. It contains tables for listing companies and their representatives in the Reggiano district.

Newspaper clipping, 1960

Ribattezzata Campoverde la frazione di Campomorto

La popolazione ha appreso con gioia la recente decisione del Presidente della Repubblica - Urge cambiare i tabelloni



zione di Carabinieri ed infine da un giorno all'altro aspettano l'inizio dei lavori per la costruzione dell'asilo nell'area donata al Comune a questo fine dalla signora Fedotti-Valdroni.

L'assistenza religiosa della popolazione è assicurata dalla piena funzionalità della Parrocchia sorta, dopo la suocera, nella chiesa che un giorno fu del marchese Mazzoni; chiesa che ogni domenica si vede piena di ogni ceto di persone, specialmente da parte degli uomini che conservano profondamente radicato nel loro cuore il sentimento della religione e del rispetto verso il loro parroco che assistono in ogni iniziativa di bene.

Coloro che si trovano lontani dalla chiesa parrocchiale hanno la loro assistenza nei giorni festivi con le messe che si celebrano nelle Cappelle di Carano, Torre del Padiglione, e Scialatella. Certamente fra qualche anno, quando la popolazione sarà triplicata, la piccola chiesa parrocchiale sarà insufficiente e sarà un problema da considerare la costruzione di una nuova chiesa parrocchiale più ampia, più funzionale e con locali annessi per le opere parrocchiali.

Poco che in mezzo a tanto frotte di opere si tengano in un completo abbandono le strade che uniscono la campagna con il centro della frazione.

Campomorto, la frazione in Comune di Aprilia, posta sulla strada statale 148 centro agricolo di notevole importanza, ha cambiato nome; da pochi giorni si chiama, infatti, Campoverde.

Con grande entusiasmo la popolazione ha appreso la notizia da tanti anni sospirata, perché l'infuato nome, molato da opere leggeree e dalle febbri miediali che un giorno vi remavano, non si addice più alla sorridente frazione che ora sta sorgendo intorno ai campi verdi rodenti dal lavoro dell'uomo. Coste, che ogni più che mai sono di attualità, i veri con cui l'Alardi descrive queste terre: «Quasi tappeto di smeraldi adorno / Si piaccia, s'allunga, e da si dense / famiglie di vivaci erbe sorrisa, / che il pare un tempo».

La frazione che prende oggi il nome di Campoverde, situata sulla strada statale 148, a pochi chilometri dalle spiagge di Nettuno, unita ai Caselli Romani per mezzo della strada asfaltata del Cinque Archi, è sorta quasi obbligatoria nei numerosi turisti e camionisti che percorrono la monotona strada statale, attirati dalla buona cucina delle trattorie che sorgono vicinissime alla strada. La speranza di cui il simbolo è rinchiuso nel suo nome: Campo, verde, la vedremo cambiarsi nella più bella realtà, quando fra breve, la piccola frazione si convertirà in un centro industriale di un certo rilievo. In effetti, sono già da tempo iniziati i lavori per la costruzione di uno stabilimento che «Recordati», industria chimica di Milano farà sorgere in questa frazione. Come abbiamo potuto vedere nello studio tecnico dell'Ingegneria si tratta di un grandioso complesso comprendente una trentina di palazzine

Did you know that Recordati got a town's name changed?



The International Prize for Scientific Research
Arrigo Recordati

Did you know that Recordati established a major international award to foster pharmaceutical research?

In the early 1960s, Recordati began building a pharmaceutical chemical plant in the countryside south of Rome, in an area then known as Campomorto, meaning "Dead Field". Unsurprisingly, no one wanted to see "Made in Dead Field" on medicine labels. Arrigo Recordati therefore petitioned the local authorities, and on 16 February 1960 the area was officially renamed Campoverde, meaning "Green Field". Today, we continue our industrial operations there, building on a long tradition of pharmaceutical manufacturing.



Campoverde site today


In 2000, the company launched the Arrigo Recordati Prize for Scientific Research in honour of its former leader Arrigo Recordati. The prize, now focused on rare diseases, awards an impressive € 250,000 research grant to innovative projects tackling orphan diseases. This longstanding prize underscores Recordati's commitment to medical innovation and scientific excellence.




Construction of the Campoverde site, 1960s



1920



Did you know that Recordati's historical advertising once blended art and science in striking ways?



In the mid 20th century, our over-the-counter product posters didn't look like typical ads. They drew inspiration from artistic movements such as Futurism, Surrealism and Cubism, creating a bold visual language that set Recordati apart. These designs are preserved in our archives, which trace the evolution of Recordati's imagery across decades.



The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the Recordati group's activities and therefore, as such, it is not intended as medical scientific indication or recommendation, nor as advertising. iStock images are included for illustrative purposes only.

Produced by Recordati S.p.A.
Concept and graphic design by TATOMMI
Photography: Archivio Recordati, Riccardo Sarri, Matteo Gastel, iStock

Published in May 2026